Products - Peritoneal cancer | Topic | NICE

Showing 7 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
17 December 2025
Expected publication date:
12 March 2026
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC